| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRECAN.2016.12.005 |
| P698 | PubMed publication ID | 28718444 |
| P50 | author | Elke Pogge von Strandmann | Q47008822 |
| Rolf Müller | Q42317495 | ||
| P2093 | author name string | Silke Reinartz | |
| Uwe Wager | |||
| P2860 | cites work | Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis | Q24307717 |
| Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors | Q24312920 | ||
| Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer | Q26780387 | ||
| Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis | Q26851836 | ||
| The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges | Q26851852 | ||
| Regulation of ovarian cancer stem cells or tumor-initiating cells | Q26853096 | ||
| Tumor infiltrating lymphocytes in ovarian cancer | Q27021878 | ||
| Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. | Q27853177 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| The role of immune checkpoint inhibition in the treatment of ovarian cancer | Q28077924 | ||
| Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism | Q28538384 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
| DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells | Q33878937 | ||
| Hematogenous metastasis of ovarian cancer: rethinking mode of spread | Q33908024 | ||
| Getting Syk: spleen tyrosine kinase as a therapeutic target. | Q33993750 | ||
| Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis | Q34026088 | ||
| Ovarian cancer development and metastasis | Q34086819 | ||
| Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth | Q34147708 | ||
| Recent insights into the role of NF-kappaB in ovarian carcinogenesis | Q34152899 | ||
| Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer | Q34210036 | ||
| Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. | Q34311697 | ||
| Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models | Q34391423 | ||
| Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse | Q34516665 | ||
| Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. | Q34569371 | ||
| Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer | Q34736974 | ||
| Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Q34788858 | ||
| Immunotherapeutic approaches to ovarian cancer treatment | Q35213535 | ||
| Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. | Q35602152 | ||
| A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment | Q35656974 | ||
| Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours | Q35759295 | ||
| Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. | Q35818203 | ||
| Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives | Q35836881 | ||
| Strategies and Approaches of Targeting STAT3 for Cancer Treatment. | Q35884979 | ||
| MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells | Q35924139 | ||
| Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma | Q36037099 | ||
| Rethinking ovarian cancer: recommendations for improving outcomes | Q36050883 | ||
| Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. | Q36086967 | ||
| CD47 blockade triggers T cell-mediated destruction of immunogenic tumors | Q36137576 | ||
| Whole-genome characterization of chemoresistant ovarian cancer. | Q50272478 | ||
| Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. | Q50937600 | ||
| Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. | Q52860239 | ||
| Activation of spleen tyrosine kinase is required for TNF-α-induced endothelin-1 upregulation in human aortic endothelial cells. | Q53388229 | ||
| Shipping Drug Resistance: Extracellular Vesicles in Ovarian Cancer. | Q53775750 | ||
| An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. | Q53811493 | ||
| Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer | Q57202934 | ||
| Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer | Q82891685 | ||
| Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. | Q36358324 | ||
| IKK inhibition increases bortezomib effectiveness in ovarian cancer | Q36413454 | ||
| Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer | Q36702185 | ||
| Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. | Q36764656 | ||
| miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint | Q36875531 | ||
| Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer | Q36922131 | ||
| A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome | Q36929682 | ||
| Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress | Q36953366 | ||
| Is There a Future for AKT Inhibitors in the Treatment of Cancer? | Q36963369 | ||
| Generation of Genetically Modified Mice Using the CRISPR-Cas9 Genome-Editing System | Q36998538 | ||
| Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer | Q37022535 | ||
| Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research | Q37196532 | ||
| The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma | Q37420970 | ||
| Reactive oxygen species in cancer | Q37431048 | ||
| Epithelial ovarian cancer experimental models. | Q37708938 | ||
| Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy | Q37734285 | ||
| Ovarian cancer stem cells: working towards the root of stemness | Q38058671 | ||
| Revisiting STAT3 signalling in cancer: new and unexpected biological functions | Q38262473 | ||
| The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review | Q38804092 | ||
| Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer | Q38819171 | ||
| Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines | Q39034873 | ||
| Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway | Q39123447 | ||
| PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction | Q39206599 | ||
| Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells | Q39396280 | ||
| Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer | Q39430345 | ||
| Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids | Q39449455 | ||
| Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. | Q39636313 | ||
| Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma | Q39693444 | ||
| Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. | Q40400391 | ||
| Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer | Q40488126 | ||
| Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. | Q40751673 | ||
| Development of a syngeneic mouse model for events related to ovarian cancer | Q40888613 | ||
| Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer | Q41386447 | ||
| Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression | Q41437712 | ||
| Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer | Q42317503 | ||
| Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages | Q43992613 | ||
| Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer | Q46681064 | ||
| P433 | issue | 2 | |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 137-148 | |
| P577 | publication date | 2017-01-18 | |
| P1433 | published in | Trends in cancer | Q27726777 |
| P1476 | title | Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure | |
| P478 | volume | 3 |
| Q94553421 | Designer Self-Assembling Peptide Hydrogels to Engineer 3D Cell Microenvironments for Cell Constructs Formation and Precise Oncology Remodeling in Ovarian Cancer |
| Q90533388 | Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment |
| Q55274845 | Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance. |
| Q88669597 | Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion |
| Q64297735 | Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model |
| Q83229853 | FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy |
| Q90231859 | Kinase Inhibitors and Ovarian Cancer |
| Q91815494 | M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression |
| Q90168993 | Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression |
| Q101564261 | Patient-derived ovarian cancer explants: preserved viability and histopathological features in long-term agitation-based cultures |
| Q98288478 | Potential interaction between lysophosphatidic acid and tumor-associated macrophages in ovarian carcinoma |
| Q54958210 | Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells. |
| Q47398937 | Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer Microenvironment |
| Q58773649 | Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment |
| Q47773956 | Revisiting ovarian cancer microenvironment: a friend or a foe? |
| Q64899135 | Sialic acids as cellular markers of immunomodulatory action of dexamethasone on glioma cells of different immunogenicity. |
| Q92081909 | The Crowded Crosstalk between Cancer Cells and Stromal Microenvironment in Gynecological Malignancies: Biological Pathways and Therapeutic Implication |
| Q92433763 | The Fanconi Anemia Pathway in Cancer |
| Q49283462 | Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. |
| Q89520800 | Tumor modeling maintains diverse pathology in vitro |
| Q92092602 | Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C |
Search more.